Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02404220
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸UCLA, Los Angeles, California, United States
🇩🇪Medizinische Klinik und Poliklinik I, Wurzburg, Germany
Brentuximab for Newly Diagnosed Hodgkin Disease
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Mitchell Cairo
- Target Recruit Count
- 40
- Registration Number
- NCT02398240
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02359162
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelDrug: FludarabineDrug: CyclophosphamideDrug: LevetiracetamDrug: TocilizumabDrug: DexamethasoneDrug: DoxorubicinDrug: High-dose methylprednisoloneDrug: PrednisoneDrug: BendamustineDrug: VincristineDrug: RituximabDrug: IfosfamideDrug: CarboplatinDrug: MethylprednisoloneDrug: EtoposideDrug: GemcitabineDrug: OxaliplatinDrug: Cisplatin
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 307
- Registration Number
- NCT02348216
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦Princess Margaret, Toronto, Ontario, Canada
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 59
- Registration Number
- NCT02343536
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DoxorubicinDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Etoposide PhosphateRadiation: External Beam Radiation TherapyDrug: IfosfamideBiological: GanitumabRadiation: Stereotactic RadiosurgeryProcedure: Therapeutic Surgical ProcedureDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 312
- Registration Number
- NCT02306161
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 40
- Registration Number
- NCT02298283
- Locations
- 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷Hôpital André Mignot, Le Chesnay, France
🇫🇷Centre Léon Bérard, Lyon, France
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 570
- Registration Number
- NCT02285062
- Locations
- 🇺🇸
Local Institution - 151, Dallas, Texas, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸Local Institution - 161, Philadelphia, Pennsylvania, United States
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02228772
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.